Can we reliably use markers of cell cycle regulation (e.g. Ki-67, p21, p27, p53) to differentiate between benign and malignant skin tumors?
Murphy
M
M
Carlson
J A
JA
D014408:Biomarkers, Tumor / Q000592:standards*; D002453:Cell Cycle; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins / Q000032:analysis; D003937:Diagnosis, Differential; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis; D009369:Neoplasms / Q000473:pathology*; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis; D015203:Reproducibility of Results; D012878:Skin Neoplasms / Q000473:pathology*; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
D014408:Biomarkers, Tumor; C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D019394:Ki-67 Antigen; D018809:Proliferating Cell Nuclear Antigen; D016159:Tumor Suppressor Protein p53; C413374:p27 antigen